CAR - T Cell Therapy: Transformative Immunotherapeutic Approach for Blood Cancer

Abstract

Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a transformative immunotherapeutic approach for the treatment of hematological malignancies, offering significant clinical benefits in patients with relapsed or refractory blood cancers. This review provides a comprehensive overview of CAR-T cell therapy, including its structural design, therapeutic applications, current limitations, and future prospects. The article begins by discussing the major types of blood cancers, such as leukemia, lymphoma, and multiple myeloma, which represent the primary targets of CAR-T cell-based interventions. The structural components of CAR-T cells, including the antigen-recognition domain, hinge region, transmembrane domain, and intracellular signaling domains are described to highlight their role in mediating targeted antitumor activity. Furthermore, the review examines the clinical applications of CAR-T cell therapy in hematological malignancies and summarizes the therapeutic outcomes achieved in recent years. Despite remarkable efficacy, several challenges continue to limit the widespread implementation of this therapy, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, antigen escape, tumor heterogeneity, manufacturing complexities, and high treatment costs. In addition, the integration of Artificial Intelligence (AI) into CAR-T cell therapy is explored as an emerging strategy to optimize target antigen selection, predict treatment responses, enhance manufacturing processes, and improve patient monitoring and safety management. Finally, the review discusses future directions aimed at overcoming current limitations through advanced CAR designs, combination therapies, gene-editing technologies, and AI-driven precision medicine approaches. Overall, CAR-T cell therapy represents a rapidly evolving field with the potential to significantly improve outcomes for patients with blood cancers and reshape the future of personalized cancer immunotherapy.